ES2144019T3 - Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa. - Google Patents

Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.

Info

Publication number
ES2144019T3
ES2144019T3 ES94111436T ES94111436T ES2144019T3 ES 2144019 T3 ES2144019 T3 ES 2144019T3 ES 94111436 T ES94111436 T ES 94111436T ES 94111436 T ES94111436 T ES 94111436T ES 2144019 T3 ES2144019 T3 ES 2144019T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
composition containing
lipase inhibitor
amylase inhibitors
glucosidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94111436T
Other languages
English (en)
Inventor
Klaus-Dieter Bremer
Pavel Sawlewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2144019T3 publication Critical patent/ES2144019T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PREPARADO FARMACEUTICO, CONTENIENDO COMO SUSTANCIA ACTIVA UN INHIBIDOR DE GLUCOSIDASA Y/O AMILASA Y UN INHIBIDOR LIPASA Y LAS SUSTANCIAS SOPORTE FARMACEUTICAS HABITUALES.
ES94111436T 1993-08-05 1994-07-22 Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa. Expired - Lifetime ES2144019T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05

Publications (1)

Publication Number Publication Date
ES2144019T3 true ES2144019T3 (es) 2000-06-01

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94111436T Expired - Lifetime ES2144019T3 (es) 1993-08-05 1994-07-22 Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.

Country Status (24)

Country Link
US (1) US5643874A (es)
EP (1) EP0638317B1 (es)
JP (1) JP2780932B2 (es)
KR (1) KR100342285B1 (es)
CN (1) CN1076196C (es)
AT (1) ATE190503T1 (es)
AU (1) AU684793B2 (es)
BR (1) BR9403170A (es)
CA (1) CA2128044C (es)
CZ (1) CZ286202B6 (es)
DE (1) DE59409200D1 (es)
DK (1) DK0638317T3 (es)
ES (1) ES2144019T3 (es)
GR (1) GR3033643T3 (es)
HU (1) HU222346B1 (es)
IL (1) IL110510A (es)
NO (1) NO313490B1 (es)
NZ (1) NZ264142A (es)
PL (1) PL175997B1 (es)
PT (1) PT638317E (es)
RU (1) RU2141844C1 (es)
SA (1) SA94150156B1 (es)
TW (1) TW381025B (es)
ZA (1) ZA945673B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017408B1 (en) * 1997-02-05 2005-04-13 F. Hoffmann-La Roche Ag Use of tethrahydrolipstatin in the treatment of diabetes type ii
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
TR200100471T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
JP2002524410A (ja) * 1998-09-08 2002-08-06 スミスクライン・ビーチャム・コーポレイション リプスタチン誘導体−可溶性繊維錠剤
DE60012301D1 (de) 1999-01-22 2004-08-26 Hunza Di Pistolesi Elvira & C Lipoproteinkomplexe und zusammensetzungen, die diese enthalten
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
AU1238101A (en) * 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
BR0112800A (pt) * 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
IL154008A0 (en) * 2000-07-28 2003-07-31 Hoffmann La Roche New pharmaceutical composition
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
US20060029567A1 (en) 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20070009615A1 (en) * 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
EP1912968A1 (en) * 2005-08-04 2008-04-23 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
PL2002825T3 (pl) * 2007-06-14 2013-12-31 Krka Kompozycje farmaceutyczne zawierające orlistat
WO2009033483A1 (en) 2007-09-12 2009-03-19 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
CN102171206B (zh) * 2008-08-06 2014-06-25 辉瑞股份有限公司 作为mc4激动剂的二氮杂环庚烷和二氮杂环辛烷
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
CN104812737A (zh) * 2012-05-08 2015-07-29 塞利克斯比奥私人有限公司 用于治疗高血糖症的组合物和方法
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3233066B1 (en) 2014-12-17 2021-11-10 Empros Pharma AB A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK520784A (da) * 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
DE68905424T2 (de) * 1988-08-22 1993-06-24 Takeda Chemical Industries Ltd Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Also Published As

Publication number Publication date
IL110510A0 (en) 1994-11-11
EP0638317B1 (de) 2000-03-15
CN1106701A (zh) 1995-08-16
CZ182594A3 (en) 1995-02-15
RU2141844C1 (ru) 1999-11-27
JP2780932B2 (ja) 1998-07-30
RU94028653A (ru) 1996-09-10
HUT68300A (en) 1995-06-28
KR100342285B1 (ko) 2002-10-25
BR9403170A (pt) 1995-04-18
HU9402249D0 (en) 1994-09-28
SA94150156B1 (ar) 2005-05-15
US5643874A (en) 1997-07-01
ATE190503T1 (de) 2000-04-15
CA2128044A1 (en) 1995-02-06
KR950005319A (ko) 1995-03-20
DK0638317T3 (da) 2000-06-26
IL110510A (en) 1999-03-12
GR3033643T3 (en) 2000-10-31
CN1076196C (zh) 2001-12-19
ZA945673B (en) 1995-02-07
PL304557A1 (en) 1995-02-06
TW381025B (en) 2000-02-01
PT638317E (pt) 2000-07-31
NZ264142A (en) 1996-11-26
HU222346B1 (hu) 2003-06-28
NO942900L (no) 1995-02-06
CZ286202B6 (cs) 2000-02-16
AU684793B2 (en) 1998-01-08
EP0638317A1 (de) 1995-02-15
AU6883994A (en) 1995-02-16
NO313490B1 (no) 2002-10-14
CA2128044C (en) 2007-02-20
PL175997B1 (pl) 1999-03-31
JPH0753409A (ja) 1995-02-28
DE59409200D1 (de) 2000-04-20
NO942900D0 (es) 1994-08-04

Similar Documents

Publication Publication Date Title
ES2144019T3 (es) Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.
FI962315A0 (fi) Entsyymi-inhibiittorit
PT722439E (pt) Inibidores da protease de hiv
FI961524A (fi) Amylaasivariantit
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
DE59608323D1 (de) Transdermal applizierbares arzneimittel mit ace-hemmern
ES2186807T3 (es) Inhibidores de trombina.
EP0614970A3 (de) Inhibitoren der Hydroxyphenylpyruvat-Dioxygenase sowie Nachweisverfahren zur Identifizierung des Enzyms.
NZ320259A (en) Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
DE69427238T2 (de) Lager
GB2324091B (en) Metalloproteinase inhibitors
ZA966885B (en) Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
EP0687473A4 (es)
DE69431454D1 (de) Amylase Inhibitoren
AU5865794A (en) Active oxygen inhibitor composition
DE69205157D1 (de) Abgedichtetes Lager.
DE69300599D1 (de) Hydroelastisches Lager.
AU666431B2 (en) Amylase inhibitors
IT1267343B1 (it) Composizione insetticida.
DK55193D0 (da) Indfoedermagasin til arkfoedede emner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 638317

Country of ref document: ES